



Exelixis Social Media Community Guidelines

Thanks for visiting one of Exelixis' corporate social media pages. We are excited to hear from you. Please remember we work in an industry with unique regulations and sensitivities. As such, we cannot participate in any discussions that mention products (ours or otherwise) or information about specific patients or medical advice. If you have any questions or concerns about one of our products, please visit <https://www.exelixis.com/medicines> for more information.

When you engage with any of Exelixis' social media channels, you are agreeing to comply with these Community Guidelines and [Exelixis' Online Privacy Statement](#), in addition to the Terms and Conditions or other legal notices provided by Exelixis and those of the respective platform ([Twitter](#), [Facebook](#), [LinkedIn](#), [Glassdoor](#), etc.)

To make sure that the discussions stay on topic and are constructive, comments or tweets that include the following may be removed or hidden from Exelixis pages for violating our engagement guidelines:

- Mention of pharmaceutical products or brands (ours or otherwise)
- Profanity, defamatory, libelous, offensive, abusive, discriminatory or demeaning content (including images, videos and links)
- Disparaging or threatening content
- Comments that condone violence or illegal behavior
- Off-topic subjects including those that may be considered commercial advertising (e.g., sell products and services, or recruit fans and followers)
- Health or medical advice
- Any personal or identifiable information related to you or others such as an email address, mailing address, phone number, treatment history or physician information
- Content that may infringe on copyrights, trademarks or intellectual property
- Posts that are excessively repetitive and/or disruptive to the community or are spam
- Proprietary, confidential, sensitive, or nonpublic information
- Posts that do not follow channel guidelines, including LinkedIn's professional community policies, Facebook's posting guidelines, Twitter's rules and policies, or Glassdoor's community guidelines



Should you post a comment detailing any side effects of pharmaceutical products, Exelixis may need to contact you for more information. Posts of this nature may not appear or may need to be removed from our pages. This is due to legal obligations concerning drug safety reporting.

If you believe that you have experienced any medical side effects or reactions from an Exelixis product, you should consult your physician, pharmacist or other healthcare professional immediately. You may also report side effects to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please note our content is intended for U.S. audiences and our social media communities are English-speaking only and as such, any non-English language content may be removed.

Any content, views, opinions, mentions and/or replies uploaded or expressed by any person other than Exelixis are solely the views, opinions and responsibility of the person uploading or expressing them and do not necessarily reflect the opinions of Exelixis. Exelixis is not responsible for content that third parties transmit on social media.

Exelixis may provide links or references to other websites as part of its content. However, Exelixis claims no responsibility for the accuracy or content of such other sites and shall not be liable for any damages or injury arising from that content. Exelixis is not responsible for the terms and conditions, privacy policy, or content of any website accessed through links or references in our social media content.

Thank you for your interest in connecting with us on social media — we look forward to hearing from you.

Forward-Looking Statements

Information expressed by Exelixis may include forward-looking statements that involve risks and uncertainties. Actual results could differ materially from those contained in these forward-looking statements due to a number of factors, including those discussed under the caption “Risk Factors” in Exelixis’ filings with the Securities Exchange Commission and available at <https://ir.exelixis.com/financials/sec-filings>. All forward-looking statements in Exelixis’ social media platforms or websites are based upon information available to Exelixis as of the date such statements was posted, and Exelixis undertakes no obligation to update or revise any forward-looking statements contained therein, except as required by law.